Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00

Humacyte (NASDAQ:HUMA) had its price objective dropped by research analysts at Benchmark from $2.00 to $1.00 in a report released on Thursday,Benzinga reports. The firm currently has a “speculative buy” rating on the stock. Benchmark’s price target suggests a potential upside of 51.06% from the company’s previous close.

HUMA has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. TD Cowen decreased their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th. Finally, HC Wainwright boosted their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.11.

Humacyte Trading Down 0.5%

NASDAQ:HUMA opened at $0.66 on Thursday. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.55. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The stock has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $0.91. The company has a market capitalization of $146.98 million, a PE ratio of -1.18 and a beta of 2.53.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.12 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, equities research analysts expect that Humacyte will post -0.34 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In other Humacyte news, Director Kathleen Sebelius acquired 56,818 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $0.88 per share, with a total value of $49,999.84. Following the completion of the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider directly owned 272,713 shares in the company, valued at approximately $245,441.70. This represents a 14.40% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte in the second quarter valued at approximately $28,000. Cerity Partners LLC acquired a new stake in Humacyte in the second quarter valued at approximately $35,000. Equitable Holdings Inc. acquired a new position in shares of Humacyte during the third quarter worth $29,000. Finally, Imprint Wealth LLC purchased a new position in shares of Humacyte in the third quarter valued at $33,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Trending Headlines about Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Strong Phase 3 dialysis results: In the V012 trial of female dialysis patients, Humacyte’s acellular tissue-engineered vessel (ATEV) outperformed traditional AV fistula access. Patients receiving ATEV had an average of 91 additional catheter-free days, while infection rates were 6 versus 23 per 100 patient-years. The data met the primary efficacy endpoint and supports a planned supplemental BLA filing in the second half of 2026. Humacyte Reports Stronger Phase 3 Dialysis Results in Women
• Positive Sentiment: Potential regulatory and commercial milestones: Management expects the FDA to issue a PDUFA decision around May 2027, with a possible dialysis-access launch by the end of the second quarter of 2027. The FDA also accepted Humacyte’s IND for a first-in-human study of its coronary tissue-engineered vessel, with a Phase 2a CABG study planned for the third quarter of 2026. Humacyte Targets November sBLA Filing
• Positive Sentiment: Early Symvess adoption improved: Second-quarter product sales rose to $0.4 million from $0.1 million a year earlier. Humacyte is rebuilding its commercial organization and adding hospital pricing, education and market-access initiatives to increase utilization. Humacyte Second-Quarter Financial Results
• Positive Sentiment: Additional funding: Humacyte raised $57.5 million through a public offering, providing capital for commercialization, regulatory filings and pipeline development.
• Neutral Sentiment: Cash runway remains a key focus: The company reported $80.3 million in cash, cash equivalents and restricted cash at June 30, while cost reductions are expected to save approximately $14.3 million during 2026.
• Negative Sentiment: Quarterly results missed expectations: Humacyte reported a second-quarter loss of $0.16 per share versus the consensus loss estimate of $0.11, while revenue of $0.41 million fell well short of the $1.12 million estimate. Humacyte Reports Q2 Loss and Misses Revenue Estimates
• Negative Sentiment: Large losses and weak near-term profitability: Net loss was $36.8 million, and cost of goods sold increased to $1.2 million despite limited revenue. The public offering also increases the risk of shareholder dilution.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.